Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16632806 | 0.87 | MAP2K1 (0.44) | POLBRXFP1MAP2K1NAMPTGAA | |
| SCHEMBL11520744 | 0.84 | CA12 (0.46) | POLBRXFP1MAP2K1NAMPTGAA | |
| SCHEMBL1129461 | 0.83 | GABRA1 (0.38) | MAP2K1TTRALBAREGLN2 | |
| SCHEMBL1321345 | 0.81 | ALDH1A1 (0.44) | POLBRXFP1NAMPTGAAKDM4E | |
| SCHEMBL4314458 | 0.81 | NAMPT (0.41) | POLBRXFP1NAMPTGAAKDM4E | |
| SCHEMBL546514 | 0.81 | CA12 (0.61) | NAMPTGAAPTPN11CA12CA1 | |
| SCHEMBL30373299 | 0.81 | ALDH1A1 (0.44) | POLBRXFP1NAMPTGAAKDM4E | |
| SCHEMBL25247694 | 0.81 | TTR (0.44) | MAP2K1TTRALBALDH1A1CA1 | |
| SCHEMBL7068350 | 0.80 | NAMPT (0.40) | POLBRXFP1NAMPTGAAKDM4E | |
| SCHEMBL14797327 | 0.80 | NCEH1 (0.41) | POLBRXFP1NAMPTGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4653053-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4426434-B1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250197357-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2025-06-19 | — | — | US | disclosed |
| CN-119677720-A | PPARG inverse agonists and uses thereof | 弗拉雷治疗公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250084038-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2025-03-13 | — | — | US | disclosed |
| CN-119585237-A | PPARG inverse agonists and uses thereof | 弗拉雷治疗公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4489863-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| EP-4426434-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | Flare Therapeutics, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| US-11820747-B2 | PPARG inverse agonists and uses thereof | FLARE THERAPEUTICS INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230331678-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1525183-A1 | INHIBITORS OF HCV NS5B POLYMERASE | Pharmacia & Upjohn Company LLC (US) | 2005-04-27 | — | — | EP | disclosed |
| US-20040142993-A1 | Inhibitors of HCV NS5B polymerase | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004002940-A1 | INHIBITORS OF HCV NS5B POLYMERASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-01-08 | — | — | WO | disclosed |
| US-6211189-B1 | NITRIC OXIDE SYNTHASE INHIBITORS; ANTIINFLAMMATORY AGENTS, ANALGESICS | ASTRAZENECA UK LIMITED (GB) | 2001-04-03 | — | — | US | disclosed |
| CN-1268138-A | Compounds | ASTRA PHARMA PROD (GB) | 2000-09-27 | — | — | CN | disclosed |
| US-6083952-A | Compounds | ASTRA PHARMACEUTICALS LIMITED (GB) | 2000-07-04 | — | — | US | disclosed |
| EP-1000064-A1 | COMPOUNDS | AstraZeneca UK Limited (GB) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999001455-A1 | COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142993-A1 | Inhibitors of HCV NS5B polymerase | POLRMT, POLR1E, CTDSP1 | POLB 11/4885RXFP1 4544/4885MAP2K1 4688/4885 |
| US-11820747-B2 | PPARG inverse agonists and uses thereof | PPARG, PPARA, PPARD | POLB 1196/4885RXFP1 286/4885MAP2K1 3508/4885 |
| US-20250084038-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | POLB 1196/4885RXFP1 286/4885MAP2K1 3508/4885 |
| US-20250197357-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | POLB 1203/4885RXFP1 284/4885MAP2K1 3542/4885 |
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | POLB 1887/4885RXFP1 44/4885MAP2K1 3876/4885 |
| US-20230331678-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | POLB 1196/4885RXFP1 286/4885MAP2K1 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.